Neetu Saini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Neetu Saini has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Pinki Gahlot
University of Duisburg-Essen
2 shared publications- Adhish S. Walvekar
Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore, India
1 shared publication - Afsana Naaz
The Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh PA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh PA; Department of Chemical & Petroleum Engineering, University of Pittsburgh Swanson School of Engineering, Pittsburgh PA
1 shared publication Akshaya Ramachandran
Stanford University
1 shared publication- Anupam Dutta
Department of Molecular Biology and Biotechnology, Tezpur University, Assam 784028, Tezpur, India
1 shared publication - Apurva Sarin
Institute for Stem Cell Science and Regenerative Medicine
1 shared publication
Latest Publications
- Open Access
FOXP3-engineered regulatory T cells restore intestinal barrier integrity in Crohn's disease enteroids via PDGF-AA
Epithelial regeneration and barrier integrity are impaired in inflammatory bowel diseases, including Crohn's disease (CD), yet current therapies largely target immune inflammation without directly promoting mucosal repair. While regulatory T cells are classically immunomodulatory, their capacity to directly support human intestinal stem cells (ISCs) and barrier function remains unclear. In this study, we tested the hypothesis that FOXP3-expressing regulatory T cells-engineered CD4LVFOXP3 and thymic-derived Treg (tTreg)-directly support human ISC maintenance and restore epithelial barrier function independent of their immunomodulatory function. Using CD patient ISCs-derived enteroids that display disease-associated damage, we established co-culture with FOXP3-engineered Treg cell-CD4LVFOXP3 or thymic-derived Treg (tTreg). The presence of either CD4LVFOXP3 or tTreg cells enhanced enteroid growth, improved epithelial barrier function, and restored apical-basal polarity of ISCs, indicating reparative capacity. Conversely, activated conventional CD4+ T cells reduced barrier function and abrogated apical-basal polarity. Integrating secretome profiling with ligand add-back and receptor or ligand blockade, we identify the PDGF-AA_PDGFRalpha; axis as a key regulator of Treg-mediated intestinal epithelial barrier integrity, but dispensable for Treg suppressive capacity. Collectively, our data delineate a direct, human tissue-intrinsic role of FOXP3-driven Treg in the interaction with ISCs via PDGF-AA-PDGFRalpha, enhancing epithelial barrier function and positioning CD4LVFOXP3 as a treatment approach coupling immunoregulation with epithelial repair.
Open AccessFOXP3-engineered regulatory T cells restore intestinal barrier integrity in Crohn's disease enteroids via PDGF-AA
Epithelial regeneration and barrier integrity are impaired in inflammatory bowel diseases, including Crohn's disease (CD), yet current therapies largely target immune inflammation without directly promoting mucosal repair. While regulatory T cells are classically immunomodulatory, their capacity to directly support human intestinal stem cells (ISCs) and barrier function remains unclear. In this study, we tested the hypothesis that FOXP3-expressing regulatory T cells-engineered CD4LVFOXP3 and thymic-derived Treg (tTreg)-directly support human ISC maintenance and restore epithelial barrier function independent of their immunomodulatory function. Using CD patient ISCs-derived enteroids that display disease-associated damage, we established co-culture with FOXP3-engineered Treg cell-CD4LVFOXP3 or thymic-derived Treg (tTreg). The presence of either CD4LVFOXP3 or tTreg cells enhanced enteroid growth, improved epithelial barrier function, and restored apical-basal polarity of ISCs, indicating reparative capacity. Conversely, activated conventional CD4+ T cells reduced barrier function and abrogated apical-basal polarity. Integrating secretome profiling with ligand add-back and receptor or ligand blockade, we identify the PDGF-AA_PDGFRalpha; axis as a key regulator of Treg-mediated intestinal epithelial barrier integrity, but dispensable for Treg suppressive capacity. Collectively, our data delineate a direct, human tissue-intrinsic role of FOXP3-driven Treg in the interaction with ISCs via PDGF-AA-PDGFRalpha, enhancing epithelial barrier function and positioning CD4LVFOXP3 as a treatment approach coupling immunoregulation with epithelial repair.
- Open Access
- 9 September 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 5 (12) , e202201663
Methionine uptake via the SLC43A2 transporter is essential for regulatory T-cell survival
Cell death, survival, or growth decisions in T-cell subsets depend on interplay between cytokine-dependent and metabolic processes. The metabolic requirements of T-regulatory cells (Tregs) for their survival and how these are satisfied remain unclear. Herein, we identified a necessary requirement of methionine uptake and usage for Tregs survival upon IL-2 deprivation. Activated Tregs have high methionine uptake and usage to S-adenosyl methionine, and this uptake is essential for Tregs survival in conditions of IL-2 deprivation. We identify a solute carrier protein SLC43A2 transporter, regulated in a Notch1-dependent manner that is necessary for this methionine uptake and Tregs viability. Collectively, we uncover a specifically regulated mechanism of methionine import in Tregs that is required for cells to adapt to cytokine withdrawal. We highlight the need for methionine availability and metabolism in contextually regulating cell death in this immunosuppressive population of T cells.
- 9 September 2022
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 5 (12) , e202201663
Open AccessMethionine uptake via the SLC43A2 transporter is essential for regulatory T-cell survival
Cell death, survival, or growth decisions in T-cell subsets depend on interplay between cytokine-dependent and metabolic processes. The metabolic requirements of T-regulatory cells (Tregs) for their survival and how these are satisfied remain unclear. Herein, we identified a necessary requirement of methionine uptake and usage for Tregs survival upon IL-2 deprivation. Activated Tregs have high methionine uptake and usage to S-adenosyl methionine, and this uptake is essential for Tregs survival in conditions of IL-2 deprivation. We identify a solute carrier protein SLC43A2 transporter, regulated in a Notch1-dependent manner that is necessary for this methionine uptake and Tregs viability. Collectively, we uncover a specifically regulated mechanism of methionine import in Tregs that is required for cells to adapt to cytokine withdrawal. We highlight the need for methionine availability and metabolism in contextually regulating cell death in this immunosuppressive population of T cells.